NCT00111410已完成4 期
A Multicenter, Double-Blind, Randomized, Placebo Controlled Study to Estimate the Effect of Anakinra (r-metHuIL-1ra) on Vaccine Antibody Response in Subjects With Rheumatoid Arthritis (RA)
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Amgen
- 主要终点
- Proportion of subjects that achieve an anti-tetanus antibody response rate at study week 8 (4 weeks after the tetanus injection), based on a 4-fold titer development relative to week 4 (pre-vaccination)
研究概览
简要总结
The purpose of this study is to estimate the effect of anakinra, 100 mg once daily (QD), on the development of an anti-tetanus antibody response in subjects with RA after vaccination with a tetanus and diphtheria toxoids injection. In addition, this study will evaluate the general safety profile of therapy with anakinra, 100 mg QD, in subjects with RA after vaccination with a tetanus and diphtheria toxoids injection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 74 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosed with RA by American College of Rheumatology (ACR) criteria for greater than or equal to 12 weeks - Active RA with at least 3 swollen joints and 3 tender/painful joints and at least one of the following:
- •Morning stiffness greater than or equal to 45 minutes;
- •C-reactive protein (CRP) greater than or equal to 1.5 mg/dL;
- •Erythrocyte sedimentation rate greater than or equal to 28 mm/hr;
- •Stable methotrexate dose of less than or equal to 20 mg/week for 8 weeks prior to randomization;
- •Stable doses of nonsteroidal anti-inflammatory drugs (NSAIDs) and oral corticosteroids (less than or equal to 10 mg/day of prednisone or equivalent) for 4 weeks prior to randomization.
排除标准
- •Pregnant or breast-feeding women - Any uncontrolled, clinically significant systemic disease - Has total white cell count less than 3.5 x 10^9/L, a neutrophils count less than 2.0 x 10^9/L, platelet count less than 125 x 10^9/L or hemoglobin (Hgb) less than 8.0 g/dL at screening - Abnormal liver function tests (AST/ALT greater than or equal to 1.5 x the upper limit of normal at screening) - Serum creatinine greater than 1.5 x the upper limit of normal at screening - Subject recall of having tetanus toxoid or diphtheria vaccination less than 10 years prior to randomization - Has never received a primary tetanus vaccination - Any other vaccination within 12 weeks of randomization - Disease-modifying antirheumatic drugs (DMARDs) other than methotrexate - Biologics to treat RA within the previous 8 weeks of screening (e.g., etanercept, infliximab) - Subjects were treated with anakinra within 4 weeks prior to randomization
结局指标
主要结局
Proportion of subjects that achieve an anti-tetanus antibody response rate at study week 8 (4 weeks after the tetanus injection), based on a 4-fold titer development relative to week 4 (pre-vaccination)
次要结局
- Safety evaluation of serious adverse events, adverse events and laboratory assessments
- Anti-tetanus antibody titers at weeks 4 and 8
- Anti-tetanus antibody level changes from baseline to week 4
- Anti-tetanus antibody level changes from week 4 to week 8
- Antibody level of at least 0.1 IU/mL at week 8.
研究者
相似试验
进行中（未招募）
3 期
A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)Still's Disease, Juvenile OnsetStill's Disease, Adult-OnsetNCT05814159Swedish Orphan Biovitrum15
已完成
2 期
Juvenile Rheumatoid ArthritisJuvenile Chronic ArthritisNCT00037648Amgen86
终止
1 期
Treatment of Macrophage Activation Syndrome (MAS) With AnakinraMacrophage Activation SyndromeNCT02780583University of Alabama at Birmingham9
终止
1 期
Study of the Effects of Anakinra in Corticosteroid-resistant Subjects With Sudden Sensorineural Hearing LossHearing Loss, SuddenNCT02414152Andrea Vambutas2
已完成
2 期
A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty ArthritisAcute Gouty ArthritisNCT03002974Swedish Orphan Biovitrum165